Y90 Radioembolization of Colorectal Hepatic Metastases using Glass Microspheres:

This data is for glass, not SRX. But I'd highly indicative, IMO.

Also it is retrospective, so not the same weight as a phase 3 trial.

However it is claimed that the OS is about double. Goes from 4-5 months to 10 months.

All good data that should be a pointer to the SRX OS data in 2017.

http://m.jnm.snmjournals.org/conten...id=1&usestrictdates=yes&resourcetype=HWCIT&ct

Y90 Radioembolization of Colorectal Hepatic Metastases using Glass Microspheres: Safety and Survival Outcomes from a 531-Patient Multicenter Study